Proactive Investors USA & Canada

Biogen Idec (BIIB) Announces Quarterly Results
In addition to the marketed products, Biogen Idec has a number of product candidates in or near registrational stage development. It includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor ...
Biogen Idec Reports Third Quarter 2011 ResultsMarketWatch (press release)

all 138 news articles »